KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.9 million.

  • Sarepta Therapeutics' Income from Continuing Operations rose 294857.59% to $196.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $395.8 million, marking a year-over-year increase of 73977.76%. This contributed to the annual value of $235.0 million for FY2024, which is 14382.98% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Income from Continuing Operations stood at $196.9 million, which was up 294857.59% from $158.8 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Income from Continuing Operations registered a high of $196.9 million during Q2 2025, and its lowest value of -$516.8 million during Q1 2023.
  • For the 5-year period, Sarepta Therapeutics' Income from Continuing Operations averaged around -$72.2 million, with its median value being -$48.1 million (2021).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 85615.14% in 2021, then skyrocketed by 294857.59% in 2025.
  • Sarepta Therapeutics' Income from Continuing Operations (Quarter) stood at -$122.0 million in 2021, then grew by 9.94% to -$109.9 million in 2022, then skyrocketed by 141.44% to $45.5 million in 2023, then skyrocketed by 248.8% to $158.8 million in 2024, then rose by 24.02% to $196.9 million in 2025.
  • Its Income from Continuing Operations stands at $196.9 million for Q2 2025, versus $158.8 million for Q4 2024 and $33.6 million for Q3 2024.